ArticleEndocrine connections2026
Vitamin D levels and skeletal quality of life in adult Langerhans cell histiocytosis.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to prospectively evaluate the association between vitamin D optimization and quality of life (QoL) and bone metabolism in adult patients with Langerhans cell histiocytosis (LCH). DESIGN AND
methodsIn this prospective, uncontrolled, observational study, 45 adult LCH patients received individualized cholecalciferol supplementation for 3 months to achieve serum 25-hydroxyvitamin D (25(OH)D) levels ≥30 ng/mL. Skeletal-related and general QoL were assessed using the QUALEFFO-41 and SF-36 questionnaires, respectively. Biochemical markers of calcium metabolism and bone turnover were measured at baseline and follow-up. Correlation and exploratory linear regression analyses evaluated associations between changes in parameters.
resultsLevels of 25(OH)D increased significantly (22.8 ± 10.3 to 34.3 ± 8.2 ng/mL, P < 0.0005), followed by a reduction in parathyroid hormone (PTH) (55.7 ± 21.1 to 49.0 ± 15.8 pg/mL, P = 0.024). Improvements were observed in QUALEFFO-41 subdomains (household activities and mental condition) and SF-36 domains (bodily pain and emotional role limitations). C-terminal telopeptide (CTX) levels decreased (P = 0.006), consistent with reduced bone resorption. Changes in 25(OH)D were inversely correlated with changes in PTH (r = -0.35, P = 0.024), and changes in PTH were correlated with changes in CTX (r = -0.41, P = 0.007). No correlation was found between changes in 25(OH)D and CTX.
conclusionIn this uncontrolled cohort, vitamin D optimization was associated with improvements in selected QoL domains and favourable changes in calcium metabolism and bone resorption markers, supporting routine assessment and correction of vitamin D deficiency in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.